Oral Ozanimod More Effective Than Avonex in Lowering Annual Relapses in MS Patients, Phase 3 Trial Finds

Oral Ozanimod More Effective Than Avonex in Lowering Annual Relapses in MS Patients, Phase 3 Trial Finds

Publication date: Sep 06, 2019

Oral ozanimod is more effective at reducing the frequency of relapses than Avonex (interferon beta-1a) in patients with relapsing forms of multiple sclerosis (MS), and does so with reasonable safety, results of Phase 3 trial show. These findings were described in the study, – Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial ,” published in the journal The Lancet Neurology. A previous Phase 2/3 trial called RADIANCE (NCT01628393) and its two-year extension study have shown that, compared to a placebo, ozanimod significantly reduced the number of lesions visible by magnetic resonance imaging (MRI), as well as the number of MS relapses experienced by RRMS patients. Specifically, SUNBEAM compared the safety and efficacy of ozanimod capsules to that of Avonex, an injectable formulation of interferon beta-1a marketed by Biogen, in relapsing MS patients – both those with RRMS and secondary progressive MS (SPMS). -In SUNBEAM, treatment of participants with relapsing multiple sclerosis with ozanimod for at least 12 months more effectively reduced active disease based on relapses and MRI lesion counts compared with interferon beta-1a. Based on these results, the team concluded that the -SUNBEAM trial reinforces and expands the results from the RADIANCE Phase 2 trial and supports ozanimod as a potential oral treatment for patients with relapsing multiple sclerosis. “

Concepts Keywords
Avonex MRI
Biogen Magnetic resonance imaging
Brain Sphingosine-1-phosphate
Capsules Celgene
Cognitive Biogen
Cohort Interferon beta-1a
Comparator Ozanimod
Disability Multiple sclerosis
Double Blind Trial Cytokines
EMA Immunology
Europe Life sciences
European Medicines Agency Medical specialties
FDA Multiple sclerosis SUNBEAM
Frequency Opportunistic infections
Gadolinium Multiple sclerosis
Immunomodulator MS
Incidence
Inflammation
Interferon Beta 1a
Intramuscular
Lancet
Lesion
Magnetic Resonance Imaging
MRI
Multiple Sclerosis
Myelin
Neurology
Opportunistic Infections
Placebo
Primary Endpoint
Progressive
Receptors
Relapse
Sphingosine

Semantics

Type Source Name
drug DRUGBANK Ozanimod
disease MESH Relapses
drug DRUGBANK Interferon beta-1a
disease MESH multiple sclerosis
disease DOID multiple sclerosis
disease MESH relapsing-remitting multiple sclerosis
disease DOID relapsing-remitting multiple sclerosis
gene UNIPROT MUC1
gene UNIPROT S1PR1
gene UNIPROT S1PR5
disease MESH inflammation
gene UNIPROT CYREN
disease DOID SPMS
drug DRUGBANK Gadolinium
gene UNIPROT AGL
disease MESH opportunistic infections

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *